These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 9628239

  • 1. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.
    Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
    [Abstract] [Full Text] [Related]

  • 2. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
    Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.
    Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
    [Abstract] [Full Text] [Related]

  • 3. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J, Barrow BA, Levy JC, Turner RC.
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [Abstract] [Full Text] [Related]

  • 4. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [Abstract] [Full Text] [Related]

  • 5. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [Abstract] [Full Text] [Related]

  • 6. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 7. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 8. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [Abstract] [Full Text] [Related]

  • 9. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 10. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [Abstract] [Full Text] [Related]

  • 11. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 14. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Regul Pept; 2003 Jul 15; 114(2-3):115-21. PubMed ID: 12832099
    [Abstract] [Full Text] [Related]

  • 15. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.
    Diabetes; 2002 Feb 15; 51(2):424-9. PubMed ID: 11812750
    [Abstract] [Full Text] [Related]

  • 16. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
    Ahrén B, Holst JJ, Mari A.
    Diabetes Care; 2003 Oct 15; 26(10):2860-4. PubMed ID: 14514592
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun 15; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
    Diabetes Care; 2003 Mar 15; 26(3):791-8. PubMed ID: 12610039
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK, Linde B, Holst JJ, Efendić S.
    Diabetes Care; 1994 Sep 15; 17(9):1039-44. PubMed ID: 7988303
    [Abstract] [Full Text] [Related]

  • 20. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J, Hylleberg B, Ng K, Damsbo P.
    Diabetes Care; 2001 Aug 15; 24(8):1416-21. PubMed ID: 11473079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.